Phase 1 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with geographic atrophy (a form of damage to the central part of the retina) caused by dry age-related macular degeneration (AMD) in the eye being studied.
• People whose area of retinal damage in the study eye is at least a certain minimum size (roughly 2.5 square millimetres or larger), as measured by a central review centre.
• People whose vision in the study eye is reduced to a certain level or below — roughly equivalent to 20/63 or worse on a standard eye chart — at the screening and first study visits.

Who may not be able to join:

• People whose retinal damage is caused by something other than dry AMD, in either eye.
• People who have a history of, or currently have, abnormal blood vessel growth or fluid leakage in the retina in either eye.
• People who have certain other eye conditions in the study eye, such as high eye pressure (above 25 mmHg), diabetic retinopathy, or an active eye infection or inflammation.
• People who have previously received, or are currently receiving, injections into the eye for any reason in either eye — unless the treatment was a complement inhibitor specifically for geographic atrophy, and the last dose was given at least 3 months before the screening visit.
• People who have previously received any systemic (whole-body) treatment for dry AMD, not counting standard eye-health supplements or vitamins.
• People who currently use, or have previously used, a systemic complement inhibitor medication (a type of medication taken by mouth or injection that affects a part of the immune system).

Important: Always verify eligibility with the trial site directly before applying.